The education library
Testosterone: the hormone, medical treatment and evidence
Educational information, not personal medical advice. AI-assisted research and editorial preparation by AnabolicRX. Sources checked 23 October 2026. No independent clinical review has been completed. This library is associated with a supplies store; it does not sell steroids or provide instructions for nonmedical use.
Start with three different meanings
“Testosterone” may mean the hormone produced by the body, a class of prescription treatments, or a particular product. Those meanings overlap but are not interchangeable. A study of a topical gel is not automatically a study of an injectable ester, and a low laboratory value is not by itself a complete diagnosis.
Testosterone has effects across reproductive, muscle, bone and blood systems. External treatment also affects the body's own hormonal regulation. This is why a discussion focused only on muscle overlooks clinically important outcomes such as fertility and red-cell concentration. Testosterone prescribing information
Medical use begins with diagnosis
The Endocrine Society recommends diagnosing hypogonadism when compatible symptoms or signs accompany consistently low testosterone, with confirmation through repeat morning testing. Evaluation then distinguishes testicular causes from hypothalamic or pituitary causes. The guideline does not support treating every older man or prescribing testosterone specifically to improve glucose control in type 2 diabetes. Guideline, 2018
This approach respects symptoms without assuming a single explanation for them. Fatigue, sexual difficulties and changes in wellbeing deserve assessment; a marketing description such as “low energy” is not equivalent to a diagnosis. A treatment can be useful for a defined deficiency while failing to address another cause of the same symptom.
Testosterone also has a role in masculinizing hormone therapy. For example, the UK Sustanon product information includes that use. This overview does not attempt to replace gender-affirming care guidance or equate every product's authorization across countries. UK product information
Benefits supported by randomized human evidence
The Testosterone Trials enrolled 790 men aged at least 65 with low testosterone and symptoms. Over one year, gel improved sexual activity, desire and erectile function compared with placebo; mood changes were modest, and the primary vitality outcome was not significantly improved. Snyder and colleagues, 2016
The pattern matters more than a slogan that testosterone “improves everything.” Benefits varied by outcome. Participants were selected for the trial, and the findings do not establish the same results in younger people with normal testosterone or with other formulations. Symptom improvement also does not answer a long-term safety question.
Cardiovascular evidence and its limits
TRAVERSE investigated men with hypogonadism and existing cardiovascular disease or increased cardiovascular risk. Major cardiovascular events in its primary composite occurred in 7.0% receiving testosterone and 7.3% receiving placebo, meeting a prespecified noninferiority criterion. Atrial fibrillation, acute kidney injury and pulmonary embolism were observed more often with testosterone. The trial used gel. Lincoff and colleagues, 2023
Noninferiority is a trial conclusion about a defined comparison and endpoint. It does not mean that every adverse outcome was equal, that testosterone prevents cardiovascular disease, or that unsupervised exposure has been shown safe. Duration, participant selection and formulation all define the boundary of the finding.
In February 2025, the FDA changed US testosterone labeling in response to TRAVERSE and blood-pressure studies: cardiovascular boxed-warning language was removed, while blood-pressure warnings were required. This was a regulatory update, not a declaration that monitoring was unnecessary. It also was not itself a Canadian label change. FDA update
Bones: density is not the same as fewer fractures
A fracture analysis of 5,204 TRAVERSE participants found clinical fractures in 3.50% of testosterone recipients and 2.46% of placebo recipients over a median 3.19 years. It did not demonstrate fracture prevention. Snyder and colleagues, 2024
An intervention can change bone measurements without producing the hoped-for change in fracture outcomes. A complete bone-health discussion therefore needs actual fracture evidence and the person's overall situation, rather than assuming hormone replacement covers every aspect of osteoporosis care.
Fertility, blood and other risks
Prescribing information identifies suppression of sperm production, increased red-cell concentration, fluid retention and changes in lipids, alongside skin, breast and mood effects. These are not all visible from how someone feels. An apparently satisfactory symptom response cannot establish that every other effect is acceptable. Prescribing information
The Endocrine Society advises against starting therapy in several situations, including near-term fertility plans, elevated haematocrit, untreated severe sleep apnoea, uncontrolled heart failure, recent heart attack or stroke, thrombophilia and certain breast or prostate findings. These are reasons for clinical assessment, not a self-clearance checklist. Guideline
Interactions involving anticoagulants, diabetes medicines and corticosteroids can affect bleeding-related monitoring, glucose or fluid retention. A pharmacist or clinician needs the full medication list; this overview does not recommend changing those medicines independently. Prescribing information
Replacement evidence is not enhancement evidence
Studies of supervised replacement address a different question from nonmedical exposure. Differences in underlying health, products, amounts, co-exposures and monitoring prevent a simple transfer of trial reassurance. Equally, recognizing those limits should not erase the genuine medical benefits of treating a diagnosed condition.
The most useful questions are specific: Which patients were studied? Which formulation? What improved? What did not? Which harms were measured, and for how long? These questions make an educational profile more useful than a broad “safe” or “unsafe” label detached from context.
Canadian context and scope
Testosterone is included in Schedule IV of Canada's Controlled Drugs and Substances Act. Authorization and marketing status are product-specific. This overview does not certify a current Canadian product list or provide sourcing advice. Official schedule
This overview does not establish current Canadian product availability or replace a Canadian prescribing monograph. Its scope is selected clinical evidence, not a comprehensive clinical reference. References are linked alongside the claims they support.
Scope and limitations
Current Canadian product authorization has not been established here. Historical labels and foreign approvals are identified as such. Some evidence was checked at abstract level; where full results were unavailable, no additional findings are inferred. The article is not a current treatment guideline or a complete account of all possible adverse effects.